Citron

GameStop's Short Squeeze Anniversary: A Look Back At David Vs. Goliath Battle And What's Next (CORRECTED)

'So Much Is Wrong:' Short-Seller Andrew Left Says 'Roaring Kitty' Trying To Take Advantage Of Retail Traders After Revealing Huge GameStop Position

The 'Most Ridiculous IPO' Of 2020? Citron Hits DoorDash With $40 Target

'So Much Is Wrong:' Short-Seller Andrew Left Says 'Roaring Kitty' Trying To Take Advantage Of Retail Traders After Revealing Huge GameStop Position

The 'Most Ridiculous IPO' Of 2020? Citron Hits DoorDash With $40 Target

Citron Research Says Tesla Shares Are Doing 'Too Much Too Fast'

Citron Thinks Peloton's Stock Is Going To $5, Compares It To GoPro

Citron Research Says Tesla Shares Are Doing 'Too Much Too Fast'

Citron Thinks Peloton's Stock Is Going To $5, Compares It To GoPro

Citron Claims Alexandria Ocasio-Cortez Is Just What Twitter Needs

Cronos Group, Analyst Respond To Citron's Short Report

Citron Recent News

PolarityTE's Stock Falls 30% After Citron Calls It A Fraud

The Long And The Short Of It: Bitcoin Bull, Bear Weigh In On Huge Move

Veritone Comes Crashing Back To Earth

'All Timing': Citron Covers Helios And Matheson Short

The Polarizing Story That Is Shopify

Citron's Andrew Left Hits The Airwaves To Explain His Bullish BlackBerry Stance

Andrew Left Doubles Down On Wayfair Thesis

Citron Research On AveXis: This Will Be One Of 2017's Biotech Blowups

Andrew Left Challenges Mallinckrodt, Compares Acthar To The EpiPen

Mallinckrodt Spikes On Citron Tweet

Citron: Mallinckrodt Makes Valeant Look Like Choirboys

Buy The Dip In j2 Global, Susquehanna Says

Fitbit On The Rise As Citron Comes Out Positive

Tesla Short Sellers Paying Much Higher Interest To Bet Against Company

Tesla's Apparent Oil Correlation Doesn't Make Stock A Buy: Why Citron Is Short

Valeant Gets Closer To Left's $50 Target After New Accounting Fears

Critical Of Monster's Valuation, Citron Anticipates A Drop To $80

EXCLUSIVE: Philidor Calls Short-Sellers 'Discredited' And 'Patently False'; Citron's Andrew Left Responds

JPMorgan Analyst Defends Valeant, Cites Continued Performance Of Two-Thirds Revenue

Mallinckrodt The Latest To Feel Citron's Wrath, Has Significantly More Downside Than Valeant

Valeant Pharmaceuticals Trading Higher

Valeant Denies Citron's 'Erroneous' Report; Analysts Also Cast Doubt

Citron Calls Valeant The 'Pharmaceutical Enron,' Sees 60% Downside In Stock